These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4954195)

  • 1. The metabolic fate of tritiated methotrexate. I. Absorption, excretion, and distribution in mice, rats, dogs and monkeys.
    Henderson ES; Adamson RH; Denham C; Oliverio VT
    Cancer Res; 1965 Aug; 25(7):1008-17. PubMed ID: 4954195
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacology of a new triazine antifolate in mice, rats, dogs, and monkeys.
    Cashmore AR; Skeel RT; Makulu DR; Gralla EJ; Bertino JR
    Cancer Res; 1975 Jan; 35(1):17-22. PubMed ID: 803254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1973 Jun; 33(6):1290-4. PubMed ID: 4718678
    [No Abstract]   [Full Text] [Related]  

  • 4. The intracellular concentration dependence of antifolate inhibition of DNA synthesis in L1210 leukemia cells.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1974 Dec; 34(12):332-40. PubMed ID: 4429954
    [No Abstract]   [Full Text] [Related]  

  • 5. The return of antimetabolite sensitivity in methotrexate- and 6-mercaptopurine-resistant L1210 murine leukemia by the process of adaptive selection.
    Wallerstein H; Slater LM; Eng B; Calman N
    Cancer Res; 1972 Oct; 32(10):2235-40. PubMed ID: 5080766
    [No Abstract]   [Full Text] [Related]  

  • 6. Sites of action of amethopterin: intrinsic and acquired drug resistance.
    Harrap KR; Hill BT; Furness ME; Hart LI
    Ann N Y Acad Sci; 1971 Nov; 186():312-24. PubMed ID: 5289423
    [No Abstract]   [Full Text] [Related]  

  • 7. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.
    Henderson ES; Adamson RH; Oliverio VT
    Cancer Res; 1965 Aug; 25(7):1018-24. PubMed ID: 4284746
    [No Abstract]   [Full Text] [Related]  

  • 8. Reversal of resistance to methotrexate in L1210 murine leukemia by uracil.
    Wallerstein H; Slater LM; Eng B; Calman N
    Blood; 1971 Nov; 38(5):648-56. PubMed ID: 5094586
    [No Abstract]   [Full Text] [Related]  

  • 9. Fate of amethopterin-resistant mutants in L1210 mouse leukemia populations.
    Hoshino A; Albrecht AM; Hutchison DJ
    Cancer Res; 1966 May; 26(5):974-8. PubMed ID: 5934806
    [No Abstract]   [Full Text] [Related]  

  • 10. Uptake and distribution of 3 H-methotrexate by the murine ependymoblastoma.
    Levin VA; Clancy TP; Ausman JI; Rall DP
    J Natl Cancer Inst; 1972 Apr; 48(4):875-83. PubMed ID: 4537157
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells.
    Chu BC; Fan CC; Howell SB
    J Natl Cancer Inst; 1981 Jan; 66(1):121-4. PubMed ID: 6935452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential biochemical alteration to antifolate resistance in L1210 leukaemia.
    Sirotnak FM; Kurita S; Sargent MG; Robinson DL; Hutchison DJ
    Nature; 1967 Dec; 216(5121):1236-7. PubMed ID: 5235641
    [No Abstract]   [Full Text] [Related]  

  • 13. The absorption, distribution, excretion, and biotransformation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in animals.
    Oliverio VT; Vietzke WM; Williams MK; Adamson RH
    Cancer Res; 1970 May; 30(5):1330-7. PubMed ID: 4987693
    [No Abstract]   [Full Text] [Related]  

  • 14. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo.
    Sirotnak FM; Moccio DM; Kelleher LE; Goutas LJ
    Cancer Res; 1981 Nov; 41(11 Pt 1):4447-52. PubMed ID: 7306968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular mechanisms of cellular resistance to antifolates].
    Grzelakowska-Sztabert B
    Postepy Biochem; 1983; 29(2):167-90. PubMed ID: 6371748
    [No Abstract]   [Full Text] [Related]  

  • 16. Lack of intracellular conversion of dihydrohomofolate to tetrahydrohomofolate in leukemia cells with high levels of dihydrofolate reductase.
    Nahas A; Friedkin M
    Mol Pharmacol; 1972 May; 8(3):353-61. PubMed ID: 5040933
    [No Abstract]   [Full Text] [Related]  

  • 17. Alteration of Methotrexate by leukemic cells: loss of affinity for an anion exchange resin.
    Rothenberg SP
    Cancer Res; 1969 Nov; 29(11):2047-55. PubMed ID: 5261206
    [No Abstract]   [Full Text] [Related]  

  • 18. Methotrexate tissue distribution: prediction by a mathematical model.
    Zaharko DS; Dedrick RL; Bischoff KB; Longstreth JA; Oliverio VT
    J Natl Cancer Inst; 1971 Apr; 46(4):775-84. PubMed ID: 5573769
    [No Abstract]   [Full Text] [Related]  

  • 19. Methotrexate analogs. 2. A facile method of preparation of lipophilic derivatives of methotrexate and 3',5'-dichloromethotrexate by direct esterification.
    Rosowsky A
    J Med Chem; 1973 Oct; 16(10):1190-3. PubMed ID: 4201424
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved methotrexate therapy of murine tumors obtained by probenecid-mediated pharmacological modulation at the level of membrane transport.
    Sirotnak FM; Moccio DM; Hancock CH; Young CW
    Cancer Res; 1981 Oct; 41(10):3944-9. PubMed ID: 7285003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.